ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-10C7895
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Eptacog Alfa Recombinant Human Coagulation Factor VIIa Market Insights and Forecast to 2028
BUY CHAPTERS

Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Research Report 2025

Code: QYRE-Auto-10C7895
Report
July 2025
Pages:106
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
BMS
Generium
Novo Nordisk
Shire (Baxter)
Bayer
CSL Limited
Pfizer Inc
Grifols S A
Biogen
Octapharma AG
NovoNordisk
Greencross
Kedrion S p A
BPL
Hualan Bio
RAAS
Suzhou Alphamab

Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size

The global market for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) was valued at US$ 1207 million in the year 2024 and is projected to reach a revised size of US$ 1490 million by 2031, growing at a CAGR of 3.1% during the forecast period.

Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market

Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (Recombinant Human Coagulation Factor VIIa).
The Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Report

Report Metric Details
Report Name Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market
Accounted market size in year US$ 1207 million
Forecasted market size in 2031 US$ 1490 million
CAGR 3.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • 60 KIU
  • 50 KIU
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company BMS, Generium, Novo Nordisk, Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Suzhou Alphamab
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market growing?

Ans: The Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market witnessing a CAGR of 3.1% during the forecast period 2025-2031.

What is the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market size in 2031?

Ans: The Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market size in 2031 will be US$ 1490 million.

Who are the main players in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market report?

Ans: The main players in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market are BMS, Generium, Novo Nordisk, Shire (Baxter), Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, BPL, Hualan Bio, RAAS, Suzhou Alphamab

What are the Application segmentation covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market report?

Ans: The Applications covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market report are Bleeding, Surgery Assisted, Glanzmann Plateletasthenia, Hemophilia B, Hemophilia A, Head Trauma, Others

What are the Type segmentation covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market report?

Ans: The Types covered in the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market report are 60 KIU, 50 KIU

Recommended Reports

Coagulation Analyzers

Recombinant Clotting Factors

Hemostasis & Thrombin

1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Overview
1.1 Product Definition
1.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Type
1.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Value Comparison by Type (2024 VS 2031)
1.2.2 60 KIU
1.2.3 50 KIU
1.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Application
1.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Value by Application (2024 VS 2031)
1.3.2 Bleeding
1.3.3 Surgery Assisted
1.3.4 Glanzmann Plateletasthenia
1.3.5 Hemophilia B
1.3.6 Hemophilia A
1.3.7 Head Trauma
1.3.8 Others
1.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size Estimates and Forecasts
1.4.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue 2020-2031
1.4.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales 2020-2031
1.4.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Competition by Manufacturers
2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Manufacturers (2020-2025)
2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Product Type & Application
2.7 Global Key Manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Date of Enter into This Industry
2.8 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Competitive Situation and Trends
2.8.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players Market Share by Revenue
2.8.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Scenario by Region
3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region: 2020-2031
3.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region: 2020-2025
3.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region: 2026-2031
3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region: 2020-2031
3.3.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region: 2020-2025
3.3.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region: 2026-2031
3.4 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Facts & Figures by Country
3.4.1 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2031)
3.4.3 North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Facts & Figures by Country
3.5.1 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2031)
3.5.3 Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Facts & Figures by Region
3.6.1 Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2020-2031)
3.6.3 Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Facts & Figures by Country
3.7.1 Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2031)
3.7.3 Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Facts & Figures by Country
3.8.1 Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2031)
3.8.3 Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2020-2031)
4.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2020-2025)
4.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Type (2026-2031)
4.1.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2020-2031)
4.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2020-2031)
4.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2020-2025)
4.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Type (2026-2031)
4.2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2020-2031)
4.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Type (2020-2031)
5 Segment by Application
5.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2020-2031)
5.1.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2020-2025)
5.1.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Application (2026-2031)
5.1.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2020-2031)
5.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2020-2031)
5.2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2020-2025)
5.2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Application (2026-2031)
5.2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application (2020-2031)
5.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Application (2020-2031)
6 Key Companies Profiled
6.1 BMS
6.1.1 BMS Company Information
6.1.2 BMS Description and Business Overview
6.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.1.4 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.1.5 BMS Recent Developments/Updates
6.2 Generium
6.2.1 Generium Company Information
6.2.2 Generium Description and Business Overview
6.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.2.5 Generium Recent Developments/Updates
6.3 Novo Nordisk
6.3.1 Novo Nordisk Company Information
6.3.2 Novo Nordisk Description and Business Overview
6.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.3.5 Novo Nordisk Recent Developments/Updates
6.4 Shire (Baxter)
6.4.1 Shire (Baxter) Company Information
6.4.2 Shire (Baxter) Description and Business Overview
6.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.4.5 Shire (Baxter) Recent Developments/Updates
6.5 Bayer
6.5.1 Bayer Company Information
6.5.2 Bayer Description and Business Overview
6.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.5.5 Bayer Recent Developments/Updates
6.6 CSL
6.6.1 CSL Company Information
6.6.2 CSL Description and Business Overview
6.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.6.4 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.6.5 CSL Recent Developments/Updates
6.7 Pfizer
6.7.1 Pfizer Company Information
6.7.2 Pfizer Description and Business Overview
6.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Grifols
6.8.1 Grifols Company Information
6.8.2 Grifols Description and Business Overview
6.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.8.5 Grifols Recent Developments/Updates
6.9 Biogen
6.9.1 Biogen Company Information
6.9.2 Biogen Description and Business Overview
6.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.9.5 Biogen Recent Developments/Updates
6.10 Octapharma
6.10.1 Octapharma Company Information
6.10.2 Octapharma Description and Business Overview
6.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.10.5 Octapharma Recent Developments/Updates
6.11 NovoNordisk
6.11.1 NovoNordisk Company Information
6.11.2 NovoNordisk Description and Business Overview
6.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.11.4 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.11.5 NovoNordisk Recent Developments/Updates
6.12 Greencross
6.12.1 Greencross Company Information
6.12.2 Greencross Description and Business Overview
6.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.12.5 Greencross Recent Developments/Updates
6.13 Kedrion
6.13.1 Kedrion Company Information
6.13.2 Kedrion Description and Business Overview
6.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.13.5 Kedrion Recent Developments/Updates
6.14 BPL
6.14.1 BPL Company Information
6.14.2 BPL Description and Business Overview
6.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.14.4 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.14.5 BPL Recent Developments/Updates
6.15 Hualan Bio
6.15.1 Hualan Bio Company Information
6.15.2 Hualan Bio Description and Business Overview
6.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.15.5 Hualan Bio Recent Developments/Updates
6.16 RAAS
6.16.1 RAAS Company Information
6.16.2 RAAS Description and Business Overview
6.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.16.4 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.16.5 RAAS Recent Developments/Updates
6.17 Suzhou Alphamab
6.17.1 Suzhou Alphamab Company Information
6.17.2 Suzhou Alphamab Description and Business Overview
6.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, Revenue and Gross Margin (2020-2025)
6.17.4 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Portfolio
6.17.5 Suzhou Alphamab Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Chain Analysis
7.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Mode & Process Analysis
7.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Marketing
7.4.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Channels
7.4.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors
7.5 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customer Analysis
8 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Dynamics
8.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Trends
8.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Drivers
8.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Challenges
8.4 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
BMS
Generium
Novo Nordisk
Shire (Baxter)
Bayer
CSL Limited
Pfizer Inc
Grifols S A
Biogen
Octapharma AG
NovoNordisk
Greencross
Kedrion S p A
BPL
Hualan Bio
RAAS
Suzhou Alphamab
List of Tables
 Table 1. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Product Type & Application
 Table 12. Global Key Manufacturers of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2020-2025) & (K Units)
 Table 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2020-2025)
 Table 19. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2026-2031) & (K Units)
 Table 20. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2026-2031)
 Table 21. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Region (2020-2025)
 Table 23. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Region (2026-2031)
 Table 25. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2025) & (K Units)
 Table 27. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2026-2031) & (K Units)
 Table 28. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units) by Type (2020-2025)
 Table 51. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units) by Type (2026-2031)
 Table 52. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2020-2025)
 Table 53. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Type (2026-2031)
 Table 54. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2020-2025)
 Table 57. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Type (2026-2031)
 Table 58. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units) by Application (2020-2025)
 Table 61. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units) by Application (2026-2031)
 Table 62. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2020-2025)
 Table 63. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Application (2026-2031)
 Table 64. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application (2020-2025)
 Table 67. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Application (2026-2031)
 Table 68. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit) by Application (2026-2031)
 Table 70. BMS Company Information
 Table 71. BMS Description and Business Overview
 Table 72. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 74. BMS Recent Developments/Updates
 Table 75. Generium Company Information
 Table 76. Generium Description and Business Overview
 Table 77. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 79. Generium Recent Developments/Updates
 Table 80. Novo Nordisk Company Information
 Table 81. Novo Nordisk Description and Business Overview
 Table 82. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 84. Novo Nordisk Recent Developments/Updates
 Table 85. Shire (Baxter) Company Information
 Table 86. Shire (Baxter) Description and Business Overview
 Table 87. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 89. Shire (Baxter) Recent Developments/Updates
 Table 90. Bayer Company Information
 Table 91. Bayer Description and Business Overview
 Table 92. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 94. Bayer Recent Developments/Updates
 Table 95. CSL Company Information
 Table 96. CSL Description and Business Overview
 Table 97. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 99. CSL Recent Developments/Updates
 Table 100. Pfizer Company Information
 Table 101. Pfizer Description and Business Overview
 Table 102. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 104. Pfizer Recent Developments/Updates
 Table 105. Grifols Company Information
 Table 106. Grifols Description and Business Overview
 Table 107. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 109. Grifols Recent Developments/Updates
 Table 110. Biogen Company Information
 Table 111. Biogen Description and Business Overview
 Table 112. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 114. Biogen Recent Developments/Updates
 Table 115. Octapharma Company Information
 Table 116. Octapharma Description and Business Overview
 Table 117. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 119. Octapharma Recent Developments/Updates
 Table 120. NovoNordisk Company Information
 Table 121. NovoNordisk Description and Business Overview
 Table 122. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 124. NovoNordisk Recent Developments/Updates
 Table 125. Greencross Company Information
 Table 126. Greencross Description and Business Overview
 Table 127. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 129. Greencross Recent Developments/Updates
 Table 130. Kedrion Company Information
 Table 131. Kedrion Description and Business Overview
 Table 132. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 134. Kedrion Recent Developments/Updates
 Table 135. BPL Company Information
 Table 136. BPL Description and Business Overview
 Table 137. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 139. BPL Recent Developments/Updates
 Table 140. Hualan Bio Company Information
 Table 141. Hualan Bio Description and Business Overview
 Table 142. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 144. Hualan Bio Recent Developments/Updates
 Table 145. RAAS Company Information
 Table 146. RAAS Description and Business Overview
 Table 147. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 149. RAAS Recent Developments/Updates
 Table 150. Suzhou Alphamab Company Information
 Table 151. Suzhou Alphamab Description and Business Overview
 Table 152. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product
 Table 154. Suzhou Alphamab Recent Developments/Updates
 Table 155. Key Raw Materials Lists
 Table 156. Raw Materials Key Suppliers Lists
 Table 157. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors List
 Table 158. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Customers List
 Table 159. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Trends
 Table 160. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Drivers
 Table 161. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Challenges
 Table 162. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Restraints
 Table 163. Research Programs/Design for This Report
 Table 164. Key Data Information from Secondary Sources
 Table 165. Key Data Information from Primary Sources
 Table 166. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa)
 Figure 2. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Share by Type: 2024 & 2031
 Figure 4. 60 KIU Product Picture
 Figure 5. 50 KIU Product Picture
 Figure 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Share by Application: 2024 & 2031
 Figure 8. Bleeding
 Figure 9. Surgery Assisted
 Figure 10. Glanzmann Plateletasthenia
 Figure 11. Hemophilia B
 Figure 12. Hemophilia A
 Figure 13. Head Trauma
 Figure 14. Others
 Figure 15. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (2020-2031) & (K Units)
 Figure 18. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Average Price (US$/Unit) & (2020-2031)
 Figure 19. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Report Years Considered
 Figure 20. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Share by Manufacturers in 2024
 Figure 21. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players: Market Share by Revenue in Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in 2024
 Figure 23. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2020-2031)
 Figure 26. North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2020-2031)
 Figure 27. U.S. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2020-2031)
 Figure 30. Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Region (2020-2031)
 Figure 38. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Taiwan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Indonesia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Thailand Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Malaysia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Philippines Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2020-2031)
 Figure 49. Latin America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2020-2031)
 Figure 50. Mexico Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Brazil Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Argentina Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share by Country (2020-2031)
 Figure 54. Middle East and Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share by Country (2020-2031)
 Figure 55. Turkey Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Saudi Arabia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 57. UAE Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 58. Global Sales Market Share of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Type (2020-2031)
 Figure 59. Global Revenue Market Share of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Type (2020-2031)
 Figure 60. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit) by Type (2020-2031)
 Figure 61. Global Sales Market Share of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Application (2020-2031)
 Figure 62. Global Revenue Market Share of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Application (2020-2031)
 Figure 63. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit) by Application (2020-2031)
 Figure 64. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Value Chain
 Figure 65. Channels of Distribution (Direct Vs Distribution)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

Global Eptacog Alfa rFVIIa Market Research Report 2025
Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Human Coagulation VIIa Market Research Report 2025
Global Recombinant Activated Coagulation Factor VII Market Research Report 2025
Global Human Coagulation Factor VII Market Insights Forecast to 2030
Global Eftrenonacog Alfa Market Research Report 2025
Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Human Thrombin for Surgical Hemostasis Market Research Report 2024
Global Recombinant Coagulation Factors Market Insights Forecast to 2030
Biological Hemostatic Material Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Eptifibatide API Market Research Report 2024
Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Human Fibrinogen Market Insights Forecast to 2030
Fibrinogen Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Topical Recombinant Human Thrombin Market Research Report 2024
Plasma derived Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Recombinant Coagulation Factor Concentrate Market Research Report 2024
Global Human Coagulation Factor IX Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions